Enzyme replacement therapy for mild patients with Gaucher disease.
Zimran
Ari
A
Ilan
Yaron
Y
Elstein
Deborah
D
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005776:Gaucher Disease / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000401:mortality; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use; D005963:Glucosylceramides / Q000378:metabolism*; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000235:genetics; D008017:Life Expectancy; D051379:Mice; D018448:Models, Immunological; D015337:Multicenter Studies as Topic; D009154:Mutation; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000276:immunology; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012042:Registries; D012641:Selection, Genetic
D005963:Glucosylceramides; D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase